Too much reliance for the recognition of shock has been placed on the sphygmomanometer, an almost worthless instrument in shock. First, it is inaccurate. Cohn (1967 Cohn ( , 1970 showed that the average error in underestimating arterial pressure with a cuff in shock is 15 mmHg, but the error may be 50 or 100 mmHg, especially when the patient is vasoconstricted by his own sympathetic reflex responses to shock or by the drugs you give him. Probably the worst error in shock is to drive the patient's arterial pressure too high with vasoconstrictors; in this case, underestimation of pressure with the cuff can be devastating. Our practice is to remove the cuff from the room whenever the patient has shock or is being resuscitated, to prevent inaccurate data from being collected. If you must use a cuff, at least ensure that everyone also palpates the carotid and femoral pulses, for you can readily recognize the problem when the cuff reads the arterial pressure as 60/40 but the central pulses are booming. With a little practice you can estimate both the mean arterial pressure and the stroke volume from central pulse palpation.
Even if arterial pressures are measured accurately with an intra-arterial catheter, low pressure alone does not make the diagnosis of shock. Patients with large blood volumes who are kept horizontal may perfuse all their critical organs adequately with very low arterial pressures. On the other hand, I believe the patient with a discharging phaochromocytoma or accelerated hypertension has all the features of shock with ischmmia of brain, heart, and kidneys. The important component of perfusion is not pressure, but flow.
Total flow (cardiac output) is not the best measure of perfusion in shock. If cardiac output is less than 2 1 per min/m2 then there is almost certainly inadequate perfusion. But in trauma and sepsis the total flow may be greater than normal, by 50% or more, with inadequate perfusion of critical organs and shock. Even within a single organ total flow does not tell the whole story, for some capillary beds may be wide open with many times their usual flow (so that this flow is wasted -'shunted'), while neighbouring capillary beds are closed and their adjacent cells are ischwmic and dying. This maldistribution of flow within critical organs is difficult to measure directly, but its effects on organ function are the most important clinical and metabolic parameters of shock. The brain and kidney are sensitive indicators of perfusion adequacy, and mental status and urine flow should be the parameters recorded on the vital sign sheet, not blood pressure, pulse, respiration and temperature. The respiratory centre responds to ischamia, and tachypncea, hyperpncea, and hypocarbic alkalosis are common early in shock. The vasomotor and cardiac centres respond to ischwmia, or peripheral signals thereof, causing tachycardia, increased heart force, and vasoconstriction of arterioles and veins. If the patient is alert, calm, and intellectually intact, and urine flow is of adequate volume and appropriate osmolality, then shock is unlikely no matter what blood pressure and cardiac output values are recorded.
The metabolic consequences of underperfusion are reflected in the blood lactate concentration or the ratio of lactate to pyruvate, for lactate reflects to a large extent splanchnic perfusion and oxygenation. Valuable as they are, one must be careful in using lactate concentrations alone, because of the 'wash out' phenomenonafter perfusion has been restored to ischmmic areas, the accumulated lactate may be washed out and thus increase the blood concentration for a few minutes. Adequacy of coronary perfusion may be judged by the ECG, especially the ST segment. Thus in shock the vital sign sheet should read: 'Brain kidney heart gut' with entries describing the mental status, volume and osmolality of the urine, ECG, and lactate.
There is one extremely sophisticated 'computerized' monitoring system that can be applied to the patientyour hand. The central pulses indicate arterial pressure, stroke volume, heart rate and rhythm. The peripheral pulses and skin temperature indicate cardiac output and vasoconstrictionif the fingers, toes, knees, elbows, and ears are warm, cardiac output is high, but if they are cold and blue there is vasoconstriction and a lower cardiac output. popularized use of the great toe temperature as a monitor of perfusion. Normally the great toe temperature is 28°C but with a low cardiac output this falls to 22°C and with maximum vasodilation and hyperkinetic circulation it may warm to 36°C. The toe temperature monitor costs $25, a far cry from the cost of computerized dyedilution cardiac output monitors, and it may be just as useful.
The most reliable index of the quality of patient care in shock is the amount of time the hand is applied to the patient. This is probably the reason intensive care units are built like wagon train circles at nightwith patients grouped around the outside and the doctors and nurses playing around the campfire in the middle. When you make rounds to evaluate the patients you are at the foot of the bed. You reach under the covers and grab the great toe. If it is warm you know the cardiac output is OK. You pinch itand if you get a reasonable response, then brain perfusion is OK. And if your hand is wetthen the kidney is OK too.
What kinds of shock are there? Too often we apply etiological names to shock, without considering pathophysiology. The patient who exhibits his gastro-intestinal bleeding on your shoes may have hypovolTmia, but his shock may be caused by an incidental myocardial infarct when he was hypotensive. The patient in the coronary monitoring unit may have shock caused by left ventricular dysfunction, but in my experience it is just as likely that this shock is due to excessive diuresis or sepsis from catheters left in place too long. Thus our old names for shock: 'burn shock', '38 caliber shock', 'Chevrolettelephone pole shock', may be quite misleading, and it is best to consider hemodynamic pathophysiology.
The patient with shock has dysfunction of the heart, blood volume, or blood flow distribution, or a combination of these essential parts of the circulatory system. Actually almost all patients who remain in shock for more than one hour will have dysfunction of all three components. The vasoconstrictive response to shock and changes in permeability cause loss of blood volume. The heart has limited coronary oxygen delivery in shock due to tachycardia, diastolic hypotension, and arterial oxygen desaturation, but it also has increased oxygen demand due to heightened sympathetic tone and tachycardia. Flow distribution is inefficient in the lungs and systemic tissues, and we can quantitate 'shunting' in the lungs with the formuhe of Riley et al. (1951) or use the technique for quantitating systemic 'shunt' introduced by Shoemaker, Bryan-Brown et al. (1976) and Shoemaker, Launder et al. (1976) . It is unclear to what extent this inefficiency of flow distribution is due to blood 'sludging' or 'evil humours' -vasoactive principles that are elaborated within ischemic cells, possibly by self-digestion when lysozomal enzymes leak out and attack cell proteins. Such humours circulate throughout the body, interfering with the normal precise regulation of blood flow in the microvasculature and causing what we recognize as 'shunts'.
How bad is the shock? Prognostic indices in shock, that identify potential survivors, have been developed by Siegel et al. (1967) , Cohn, Engler & Del Guercio (1975) , Cady, Weil et al. (1973) , Shubin, Afifi et al. (1968) , ), Winkel et al. (1971 ) and Shoemaker et al. (1973 , 1974a . The important question is not so much how sick the patient is now, but how to identify the parameters we should use as guidelines in therapy. We know that to make blood pressure and blood flow recordings 'normal' is not the correct approach in any patient in shock, but what parameters should we measure and what values of them are optimal?
All too often we make two mistakes. The first is to measure what is easy rather than what is pertinent. We buy expensive ECG machines that ring a bell for asystole.but that bell should ring in the morgue, because the warning should have come a minute, an hour, or a day earlier. We measure arterial pressure with 1 % precision, yet we are not 100 % sure how to change it optimally. We measure cardiac output, but what about the septic patient who has a twice normal cardiac outputsurely we shouldn't lower it to 'normal'? We should be measuring more basic parameters of cellular metabolism, perhaps the redox potential of the brain mitochondria, yet rare indeed is an intensive care unit with as much facility for measuring lactates as heart rates.
The second error we make is to measure everything at once, losing ourselves in a sea of numbers many of which are derived by arithmetical exercises from other numbers. Perhaps such derived parameters are of value, at least they sell calculators, but I have enough trouble dealing with comfortable parameters, such as arterial pressure, without grappling with new beasts like the product of arterial P02 and heart rate. The discouraging feature is that we don't really know what we should use to manage the patient. The prognostic indices tell us with great accuracy whether the patient will live or die, but such studies do not reveal by which parameters we should 'fly' the patient, and so we end up flying the patient by the seat of our pants instead of our other end.
Who is the doctor? Shock evokes a dumping syndrome. When called at 3 a.m. (the inevitable time for shock to be recognized), many physicians try to determine to which specialty (other than theirs) shock belongs. Thus shock becomes the property of cardiologists, anxsthesiologists, &c., yet shock belongs to all of us. Every patient will surely have shock once -our job is to allow him to have a second chance at it, and for this we need all medical skills. Although the intensivist, cardiologist, anesthesiologist, &c. have special skills that are helpful in the care of many patients, every patient in shock needs one personal physician who knows him best and co-ordinates all his care.
Who is the nurse? The patient in shock requires constant attention. He stands on the edge of a precipice, and any tiny shove sends him irreversibly into the chasm. A brief respirator malfunction or a sudden mucus plug may kill him in seconds, by a death we call 'arrhythmia' rather than the more accurate 'inattention'. Thus the critical care environment must have a 'zero defects' philosophy, preventing mistakes. The central figure in critical care is the nurse, for it is she who most often applies her hands to the patient, suctions his tubes, repositions him every half hour, &c. Physicians come and go through the unit and many physicians apply their skills (and hopefully their hands) to the patient, but it is the nurse who is most consistent and constant in treating the patient. Often in our race to send enough pieces of our patient to the laboratory or to balance the monitoring equipment or to listen to the chest we forget our patient is humanhe becomes a 'problem'. But this failing is our problem, and fortunately the critical care nurse does not as readily forsake the central issue. Perhaps the greatest compliment in the critical care unit is when a patient says: 'Doctor, you have been so good to me, you should have been a nurse!'. How do you treat shock? First, of course, you don't treat shock, you treat a patient. That patient has several illnesses all of which must be considered. You can't drive excessively the heart of a patient with myocardial infarction in hopes of saving his kidneys -you lose the heart, the kidneys and the whole patient. This is why the patient needs one physician and many consultants. The consultants will elegantly examine and suggest care of their parts of the body, while the patient's physician cares for the patient and his family. Second, the specific therapy of shock is to identify and treat the inciting event. If the patient has a prostatic abscess, cardiac tamponade, or a dissecting aneurysm, none of our fancy cardiotonic drugs &c. will be of any avail. We must find and treat specifically the proximate cause. The therapy of shock is really symptomaticwe juggle this parameter and that to keep the patient alive long enough to discover all his problems and correct those we can. Often we hear the patient is too sick to have general anesthesia, but in shock the portal of death yawns hungrily, and to snatch back a life we must be appropriately aggressive and say instead that the patient is too sick not to be operated upon.
Intravascular volume: The first consideration in managing shock is to optimize intravascular volume. Hypervolemia causes pulmonary cedema, but hypovolcemia causes vasoconstriction, hypo-tension, and hypoperfusion. The absolute volume may be measured by indicators (radiolabelled albumin) or inferred from changes in the hematocrit, but the absolute volume is not as important as the relationship of volume to capacitance. If the capacitance vessels are widely dilated, a blood volume much greater than 'normal' may be needed to maintain adequate venous return as reflected in heart filling pressures. If the capacitance vessels are tightly constricted, as they often are in shock, then a 'normal' blood volume may cause high filling pressures.
Instead of measuring the blood volume itself, we measure filling pressurescentral venous pressures from the right heart and left ventricular end diastolic pressures. Which of these is best? Of greatest importance are the left ventricular filling pressures, for these determine both the output from the left ventricle and the likelihood of pulmonary cdema. The left ventricular pressures may be measured directly, by a retrograde catheter passed through the aortic valve, but this is complex and dangerous. In most cases we utilize the invention of Dr Swan and Dr Ganz a balloon catheter that floats unerringly through valves and ventricle into the pulmonary artery. The pulmonary arterial diastolic pressure provides an estimate of left ventricular end diastolic pressure, but even better is the wedge pressure obtained on balloon inflation. The pulmonary arterial systolic pressure is the most efficient monitor of ventilationhypercarbia or hypoxmmia leads immediately to pulmonary vasoconstriction and increased sympathetic tone so that pulmonary arterial systolic pressures increase. Samples of pulmonary (mixed venous) blood are useful for measurement of cardiac output (Fick) and venoarterial admixture (shunting), and arteriovenous oxygen differences as an indicator of the adequacy of peripheral perfusion. When they are underperfused, peripheral tissues extract as much oxygen as they are able, and arteriovenous oxygen differences are greater than normal. When there is peripheral 'shunting' arteriovenous oxygen differences are less than normal (Siegel et al. 1967 ). Finally, the pulmonary arterial catheter contains a temperature sensor and a right atrial lumen. These permit measurement of core temperature of the patient and monitoring of central venous pressure. More important, by injection of cold solutions into the right atrium, the cardiac output can be measured accurately and quickly from the temperature changes in the pulmonary artery. Thus this single catheter measures input and output functions of both ventricles, adequacy of peripheral oxygen extraction, stability of ventilation, heart rate, and core temperatureit gets right to the heart of the monitoring problem.
Central venous pressures may still be useful in some patients. Although the right and left filling pressures are quite different in patients with myocardial infarction, lung disease, &c., these filling pressures tend to change in the same direction on any alteration of intravascular volume. In the patient with a low central venous pressure who has no signs of pulmonary congestion (as judged by auscultation, roentgenography, and oxygenation), cautious volume loading may be attempted, and if shock resolves it may not be necessary to insert a pulmonary arterial balloon catheter. In the patient who has pulmonary congestion or a high central venous pressure in shock, a balloon catheter becomes more essential than a sphygmomanometer, ECG monitor, or urethral catheter.
The Frank-Starling law of the heart states that the output function is dependent upon the input to the heart -if shock is equivalent to underperfusion we must consider augmenting filling pressures to improve output. Most patients, even after left ventricular myocardial infarction, will increase cardiac output as pulmonary wedge pressures are increased to between 14 and 18 mmHg. With the balloon catheter in place the nurse can construct the ventricular function curve, increasing wedge pressure by infusing fluids and measuring directly the changes in cardiac output. As long as shock persists and as long as there is no evident myocardial ischmmia, the law of the heart in shock is to maximize cardiac output without evoking pulmonary cedema.
What determines pulmonary cedema? The complex formulm include permeability and area factors, but Guyton et al. (1959) , , Da Luz et al. (1975) , Shwffer, Carlson et al. (1975) , Gann et al. (1975) and Puri et al. (1975) , found the relationships in shock to be simple. If the colloidal osmotic pressure remains 6 mmHg more than pulmonary wedge pressure, pulmonary oedema is unlikely. The colloidal osmotic pressure is determined largely by the concentration of albumin. In normal erect patients it is about 24 mmHg, but in the critically ill patient it averages about 18 mmHg. Many patients with liver or renal disease may have serum albumin concentrations of 1 to 2 gm/dl, and colloidal osmotic pressures of 5 to 10 mmHg. Such patients will develop pulmonary cedema with only minimal elevations of pulmonary wedge pressures.
In choosing fluids for the patient in shock, remember colloidal osmotic pressure. It the patient is given large volumes of saline, albumin is diluted, colloidal osmotic pressure decreases, and much of the saline ends up in the pulmonary interstitial spaces. Saline may be appropriate for patients who have lost extracellular fluid (via gut or kidney), but in most cases on augmenting intravascular volume it is most appropriate to maintain colloidal osmotic pressure.
Albumin is an effective colloidal agent. It is best given as concentrated (25 gm/dl) salt-poor albumin that you dilute to 5 gm/dl with saline, sodium bicarbonate, dextrose, or whatevei fluid is appropriate for the patient. Purified plasma protein fractions should not be usedthey are dissolved in saline, they cause hypotensive reactions, and they are more expensive per unit of albumin. Actually that is the only side-effect of albuminits cost. In most acute hospitals albumin and plasma proteins make up 10% of the pharmacy budget. At University Hospitals of Cleveland that is more than $125 000 per year, but at Sloan-Kettering it is more than $1 million per year, In the United States we buy about $250 million worth of these products annually. When related to its nutritional value, albumin costs $285 per hamburger equivalent.
Alternative colloidal agents are dextran-70 and hydroxyethyl starch. Dextran causes anaphylactoid reactions in 5 % of recipients, and these may be fatal. In addition it interferes with platelet function and may cause severe bleeding. Hydroxyethyl starch lasts somewhat longer in circulation than dextran, does not cause hypotensive reactions, and causes much less interference with normal coagulation mechanisms. Dextran-40 is a very short-term 'plasma substitute' that is excreted rapidly in urine and may cause renal failure due to tubular obstruction if hypotension develops after it has been given. Dextran-40 is often promoted as an anticoagulant, but its effects are much less prominent than those of heparin or warfarin; it improves blood flow, but this is accomplished solely by dilution of red cells and fibrinogen, and blood viscosity is increased if hmemodilution does not occur. As dextran-40 has all the toxicity of dextran-70, but in addition may cause renal failure, this dextran should not be used. As an alternative to expensive albumin, hydroxyethyl starch is the volkmic colloid of choice.
In the patient with pulmonary congestion and high pulmonary wedge pressures albumin alone may worsen oedema, but if the wedge pressure is reduced by vasodilation and/or diuresis, albumin may be helpful if the patient is hypovolkmic.
One common error is to rely on filling pressures alone without considering cardiovascular compliance. In the presence of heightened sympathetic tone, or when you give vasoconstrictors, the circulatory compliance is halved and a high pressure may be sustained by a small intravascular volume. This may lead to more and more vasoconstriction of arterioles and veins, maintaining filling pressures at the cost of worsening hypoperfusion. Such patients should be treated with additional volumre, and in most cases the circulatory compliance will increase and filling pressures will decline. If they do not, small doses of vasodilators will augment compliance and optimize filling pressures.
Inotropic drugs: If hypoperfusion persists when filling pressures have been optimized, the next approach is to augment contractility and thereby increase cardiac output. A variety of drugs are available, but only the directly-acting catecholamines are appropriate. These four drugs, norepinephrine, epinephrine, dopamine, and isoproterenol, have equivalent effects on heart force, but quite different effects on heart rate and systemic vascular resistance. Norepinephrine constricts most peripheral vessels, and increases preload and afterload of the heart to the greatest extent. This may be appropriate during cardiopulmonary resuscitation, but in shock it diminishes essential organ perfusion and may precipitate pulmonary cedema. Epinephrine is a forgotten drug in shock because in the usual large doses employed it resembles norepinephrine in most actions. Epinephrine, however, dilates bronchi, and in the rare case where bronchodilation is required it will be important to use either epinephrine or isoproterenol for this purpose. Isoproterenol causes tachycardia and tachyarrhythmias. It dilates skeletal muscle vessels, and although it does not constrict the vessels of the gut and kidney, it does not effectively dilate them either, so the net effect is that the fraction of cardiac output reaching the kidney is diminished. Furthermore, isoproterenol often worsens myocardial ischmmia because of the combination of tachycardia and diastolic hypotension. which minimize oxygen delivery and maximize oxygen utilization.
Dopamine offers a distinct advantage over the other inotropic drugs in shock. In doses of 200 to 500 ,ug/min,it dilates directly the renal, mesenteric, cerebral, and coronary vessels, although coronary perfusion is determined more by myocardial oxygen demands than by any vasomotor action.
In doses of 500 to 2000 [.g/min in the adult dopamine increases heart force to the same extent as the other catecholamines at comparable doses: that is, the maximum effect may triple the heart force (and myocardial oxygen requirements). At doses above 2000 ,ug/min (up to 1 000 000 ,ug/min) there is progressive alpha adrenergic vasoconstriction, resembling the action of norepinephrine. In no instance have we seen a patient in shock who had a greater pressor response to norepinephrine than to comparable doses of dopamine. Thus one drug, dopamine, can provide a spectrum of appropriate vasomotor actions and at the same time progressively increase heart force. The responsive patient with mild hypoperfusion will improve on small doses which redirect blood flow to essential organs without increasing the heart force very much. At higher doses the inotropic effects predominate, but doraminergic vasodilation maintains appropriate perfusion distribution. If the patient is very refractory to therapy and a pressor response is required to maintain arterial pressures at viable levels, then higher doses of dopamine will accomplish the necessary vasoconstruction as efficiently as any other alpha adrenergic agonist.
Dopamine clinical trials: The hemodynamic and renal function effects of dopamine have been studied in patients with shock refractory to maximum augmentation of intravascular volume and to prior therapy with isoproterenol and/or norepinephrine. In these studies all patients had gross underperfusion, with severely disturbed mental status and oliguria, and mean arterial pressures were at least 15 mmHg less than healthy values. The doses of isoproterenol, norepinephrine, and dopamine were adjusted rapidly to produce an 'optimal' response, i.e. maximal perfusion of critical organs at a mean arterial pressure about 10 mmHg less than healthy values, minimal tachycardia and no tachyarrhythmias. When the best possible response had been obtained with one drug, the comparison drug was started and the dose rate adjusted for equivalent 'optimal' perfusion; haemodynamic comparisons were then made. All patients who were sufficiently stable to tolerate a brief period without catecholamine therapy were also studied on no catecholamine, before the dopamine.
Other patients had the dosage of isoproterenol or norepinephrine optimized and then compared quickly with similar 'optimal' responses to dopamine.
Patients with cardiogenic shock were divided into five groups. Thirty patients had shock within 6 hours of the onset of definite transmural myocardial infarction. Thirty-five patients had shock more than 6 hours after such infarction. Twenty-five patients had shock after cardiac surgery and 51 others had shock due to myocardial dysfunction without definite transmural infarction. Fifteen patients had severe chronic heart failure with progressive hypoperfusion until the criteria of shock were met. Eighty-six of these patients were men; the average age was 58 years + SD 17.
One hundred and thirty-two patients had sepsis and shock. Twenty-two had gram positive infections, with positive blood cultures in 14. Eighty-five patients had gram negative infections, with positive blood cultures in 40. Five patients had fungal or tuberculous infections with shock, and 20 patients had infections as the probable cause of shock but without isolation of a definite organism. No differences were noted in the initial hemodynamics nor in the response to therapy of these groups, and they are therefore combined in the analyses. The 132 patients in this group had a mean age of 57 + 17 years; 77 were males.
Observations were also made on 20 patients with severe hepatic and renal failure, 9 patients with renal failure, 31 patients with shock of other types, and 6 patients who did not have shock.
In 119 patients with cardiogenic shock (CS) and 85 patients with infections and shock (IS), observations could be made during brief periods off catecholamine treatment. In such patients the optimal doses of dopamine averaged 650 ,tg/min, and mean arterial pressures increased promptly at these doses from 81 to 87 mmHg. This population was predominantly elderly and hypertensive. Isoproterenol was compared with dopamine in 28 CS and 43 IS patients. Optimal isoproterenol doses of 7 ,g/min maintained arterial pressures at an average of 68 mmHg with severe shock. Dopamine at average doses of 1320 (CS) or 2200 (IS) ,ug/min promptly increased mean arterial pressure to 80 mmHg with improved perfusion. These patients were relatively refractory to norepinephrine, requiring 26 (CS) or 100 (IS),ug/min to maintain mean arterial pressures of 75 mmHg with severe hypoperfusion. When dopamine was instituted in such patients (21 CS and 14 IS), mean arterial pressures increased to 80 mmHg in both groups at average dopamine doses of 850 (CS) to 1200 (IS) jtg/min. The dopamine dose-response curve was relatively flat, and in 129 CS and 144 IS patients observations were made when the dose was doubled from initial levels of 500 (CS) or 1200 (IS) tg/min: there was little further increment in arterial pressure. Adding isoproterenol to dopamine in 8 CS and 14 IS patients caused little change in mean arterial pressures.
Heart rates averaged 96 per min in 133 patients with CS, studied during brief periods of withdrawal of catecholamines, and 105 per min in 92 similar IS patients. Initiation of dopamine at 600 (CS) or 1 100 (IS) Mg/min caused an increase of only 5 (CS) or I (IS) beat per minute. Heart rates increased slightly from 104 to 109 in 31 patients with CS switched from optimal norepinephrine to equivalent dopamine, and in 19 similar patients with IS heart rates increased from 99 to 104 per min. Heart rates decreased significantly in 41 CS and 54 IS patients switched from optimal isoproterenol to dopamine. In CS, heart rates averaged 111 on isoproterenol at 6 ,ug/min but decreased to 104 on dopamine at average doses of 1200 ,ug/min. In IS, heart rates averaged 114 per min on isoproterenol at 6.5 Hg/min but decreased significantly to 105 per mm on dopamine at average doses of 3000 Hg/min. Addition of isoproterenol to dopamine in 11 CS and 19 IS patients made little difference to heart rates, and heart rates were also constant when the dopamine dose was doubled from its initial levels of 650 pg/ min (158 patients with CS) and 1200 Hg/min (145 patients with IS).
Filling pressures measured as pulmonary wedge pressures or, in a few patients, as left ventricular end diastolic or right atrial pressures, did not change significantly from their initial levels of 10.5 mmHg (in CS or IS) when dopamine was staited after a brief period of catecholamine withdrawal. However, in 20 patients with CS filling pressures averaged 13.5 mmHg on dopamine 1200 Htg/min, compared with 11.5 mmHg on optimal isoproterenol doses averaging 4 ,ug/ min. Filling pressures increased only slightly when dopamine doses were doubled, when dopamine was combined with isoproterenol, and when norepinephrine was given instead of dopamine.
Cardiac indices (thermodilution or in a few cases indocyanine green dilution) increased from 1.6 to 2.3 1 per min/m2 in 21 patients with CS given dopamine after withdrawal of catecholamines, and they increased from 1.8 to 3.4 1 per min/m2 in 12 similar patients with IS. Cardiac indices were near 11 per min/m2 during norepinephrine, and they more than doubled when dopamine was substituted. Cardiac indices remained constant at 2 1 per min/m2 (9 patients with CS) or 3 1 per min/m1 (13 patients with IS) when dopamine (1400t g/min CS, 2400 Htg/min IS) was substituted for optimal isoproterenol (7 ,ug/min). Increasing dopamine from initial optimal levels (600 Hg/min CS, 1200 g/,tmin IS) to about twice these doses caused only slight increments in cardiac index. Addition of isoproterenol to dopamine did increase cardiac indices significantly in the total of 9 patients studied.
Urine flows averaged 0.7 ml/min during brief periods of catecholamine withdrawal in patients who would tolerate it, and increased to 1.6 ml/ min in 137 patients with CS and 1.2 ml/min in 90 patients with IS on starting dopamine at 'optimal' doses of 700 and 1050 pg/min respectively. Urine flows increased from 0.4 to 1.0 ml/min in 42 patients switched from optimal norepinephrine (45 yg/min) to optimal dopamine (1500 Htg/min) in CS. In 20 patients with IS urine flow increased from 0.8 to 1.6 ml/min when optimal norepinephrine (155 ,ug/min) was switched to dopamine (8600 Hg/min). Diuresis was also noted when isoproterenol 7.5 Htg/min was switched to dopamine 1600 ,ug/min (0.45 to 1.05 ml/min) in CS and when isopt oterenol 7 [kg/min was switched to dopamine 3600 ,ug/min (0.5 to 1.25 ml/min) in 59 patients with IS. Adding isoproterenol to dopamine slightly decreased urine flow, and doubling the optimal initial dopamine doses (750 Hg/min CS, 1200 ,tg/ min IS) caused little further increase in urine flow in 166 observations in CS and 157 in IS.
Glomerular filtration rates, measured by inulin or in some cases endogenous creatinine clearances, increased significantly from 55 to 70 ml/min in 29 patients with CS given dopamine at 350 jug/min after no catecholamine, and from 12 to 15 ml/min in 17 patients with IS given dopamine at 500 ,tg/min initially after no catecholamine. Glomerular filtration rates were not significantly changed in the few patients studied after switching from norepinephrine or isoproterenol to dopamine, nor by doubling the initial optimal dopamine doses (700 pg/min in 46 CS patients, 1200 /ug/min in 44 IS patients).
Renal function studies were performed only in patients who had not received furosemide, mannitol, or other diuretics before dopamine therapy. In such patients with CS, dopamine decreased free water clearance from -0.4 to -0.5 ml/min at doses of 350 tg/min in 30 patients treated after periods of no catecholamine, but free water clearances in other patients remained relatively constant when one catecholamine was changed to another. Sodium, and to a lesser extent potassium, clearances increased during dopamine therapy, mirroring the diuretic effects.
Survival of patients in this study was quite poor, reflecting the serious prognosis of shock which is refractory to blood volume expansion and initial treatment with isoproterenol or norepinephririe. Of the 156 patients with CS, 29 left the hospital alive, 23 died more than 2 days after resolution of shock, and 80 died in shock. Of the 132 patients with IS, 20 left the hospital alive, 21 died more than 2 days after resolution ofshock, and 71 died in shock. The survival rate was somewhat better in postoperative patients with hypoperfusion and shock (13/25), and somewhat worse in patients with progressive heart failure (1/15), but otherwise it was not related to specific ,etiology. Dopamine maximum dosage was related to survival. No patient who required more than 18 000 jug/min for one hour left the hospital alive. Most survivors required dopamine doses no greater than 1800 ,tg/min (CS) or 3500 Hg/min (IS), but a few patients survived who required doses of between 5000 and 18 000 ,tg/min for periods of more than one hour. The incidence of side reactions was low in patients receiving dopamine in comparison with periods of treatment with norepinephi ine or isoproterenol, but many of these patients were referred for study because they had not responded appropriately to the other catecholamines. Tachyarrhythmias were distinctly unusual with dopamine, even in doses of 20 000 to 1 000 000 ,ug/min. Most patients who died while receiving dopamine developed gradually progressive slowing of heart rates, that became unresponsive to dopamine, isoproterenol, or pacing; tachyarrhythmic deaths on dopamine were quite rare. Side reactions to dopamine were generally not related to dose, although two patients developed angina pectoris when an infusion pump was inadvertently switched to deliver ten times the appropriate low dose.
Vasodilators: Vasodilators first became popular in shock when it was common to give inadequate intravascular volume replacement, and tightly vasoconstricted patients given vasodilators were then better perfused as additional volume was infused. Now the reverse situation is commonthe patient is given excessive intravascular volume (often crystalloidal rather than colloidal) and then as pulmonary oedema supervenes the patient is 'bailed out' with vasodilators.
Only a few patients in shock should receive vasodilators as primary therapy, and they should never be given unless filling pressures are high. Some patients with myocardial infarction present with pulmonary congestion, high filling pressures, and profound vasoconstriction. Careful vasodilation in such patients may improve perfusion, diminish myocardial oxygen requirements, and decrease filling pressures, thereby relieving pulmonary congestion. Other patients in shock who have a similar combination of excessive peripheral vasoconstriction, high filling pressures, but underperfusion can profit from the judicious and controlled administration of vasodilators. It is very important in such patients to monitor the filling pressure frequently and to measure peripheral perfusion. It is mandatory that the administration of a vasodilator be controlled by an infusion pump.
There are three vasodilators to consider. Phentolamine (Regitine) is an alpha adrenergic antagonist with a duration of action of about 30 minutes. It dilates both veins and arteries and its effects are more prominent in patients with high levels of endogenous sympathetic tone or during the administration of large doses of norepinephrine, epinephrine, or dopamine. Phentolamine is given by constant intravenous infusion at doses of 50 to 500 ,ug/min, and it may be mixed with the catecholamine in the same infusion solution. Nitroprusside (Nipride) dilates directly the smooth muscle of blood vessels, possibly with greater action on arterial vessels. Nitroprusside is given as a constant intravenous infusion at doses of 20 to 1000 ,ug/min. Its action is of short duration, one or two minutes, but care must be taken that no bolus of drug is given, as for example during flushing of the intravenous catheter. Nitroglycerine given intravenously may have a predominant action on capacitance vessels, and there is some evidence that it may improve the collateral flow to ischvmic myocardium to a greater extent than nitroprusside. There are no data concerning the relative efficacy of these three vasodilators in shock not associated with myocardial infarction, but certain basic principles apply to all of them: maintain adequate filling pressures, monitor arterial pressures carefully, use minimal doses of the vasodilator, and try to stabilize mean arterial pressures at about 10 mmHg less than healthy values. If mean arterial pressures are reduced to less than 65 mmHg coronary autoregulation and coronary myocardial oxygen delivery may be compromised.
The combination ofdopamine with vasodilators is a particularly powerful form of therapy. The alpha adrenergic vasoconstriction produced by high doses of dopamine may be attenuated with vasodilators, especially phentolamine, so that the best combination of inotropic and dopaminergic effects can be found for improving perfusion distribution and reducing pulmonary wedge pressures and pulmonary congestion.
Peripheral perfusion distribution: Often in refractory shock the inefficient microvascular flow, distribution leads to high levels of shunting in the lungs and systemic vessels. Shunting can be reduced in the lungs by the cautious use of continuous positive pressure respiration. This intervention, however, also diminishes the transmural filling pressures ofthe heart, necessitating in some cases additional intravascular volume augmentation and/or additional inotropic stimulation. Unfortunately it is particularly difficult to measure pulmonary wedge pressures during continuous positive pressure respiration. The patient cannot be removed from positive pressure or the increased filling may cause profound bradyarrhythmias and severe hypoxemia. The level of airway pressure at end expiration cannot be subtracted from pulmonary wedge pressures because of the variable distribution of this added pressure throughout the thorax. As yet there has been no satisfactory solution to this dilemma, and at high levels of positive expiratory pressure (15 + mmHg) estimation of proper filling pressures may require repeated cycles of volume augmentation and the test administration of vasodilators.
It is the decompensation of the normally finetuned microvascular blood flow distribution which remains the greatest challenge in shock.
Is it neural, humoral, or metabolic in origin? How can it be prevented? From the studies of Moss et al. (1973) and Moss & Stein (1975 , it seems certain that brain ischwmia causes pulmonary shunting and pulmonary aedema by a neural mechanism. Others have isolated humoral factors that cause many of the changes of shock in recipient animals, but it is not clear how production of these evil humours may be prevented or their effects antagonized. Glucocorticoids have been shown to stabilize lysomal enzymes, possibly preventing autodigestion in acidotic ischmmic cells, and to have numerous other beneficial actions, both in isolated tissues and in animal studies. In patients it seems certain that large doses of glucocorticoids given for a single day have minimal toxicity, although potassium, glucose, and sodium concentrations may be increased in serum. In one prospective doubleblind study of methylprednisolone (Thompson et al. 1976) (30 mg/kg given at 0, 2, 8, and 24 hours if shock persisted), no toxic reactions were noted, but survival of these patients, most of whom had infections and shock, was the same with methylprednisolone as with placebo. The initial dose of methylprednisolone in this study was given an average of nine hours after the onset of shock as determined retrospectively. Earlier therapy may be more effective, and if glucocorticoids are to be used in shock they should be given in these large doses as soon as the diagnosis is made.
Summary
Shock is a syndrome with serious prognostic implicationsthe harbinger of death. Hypoperfusion of essential organs is common, though total blood flow may be significantly greater than normal. Specific therapy is directed to the specific inciting eventinfection, abscess, tamponade, &c. Symptomatic therapy keeps the patient alive until we discover the specific problem or until he recovers spontaneously. The intravascular volume must be carefully monitored and corrected, using the pulmonary wedge pressure as the principal guide, and colloid osmotic pressure must be maintained. If the patient does not respond to volume augmentation alone then inotropic drugs may be needed, and of these dopamine is a selective vasodilator which redirects blood flow to the critical organs. The outstanding challenge in shock is the maldistribution of perfusion in the microvasculature. Although this may be ameliorated by the early administration of large doses of glucocorticoids, there is little convincing that these drugs constitute more than supportive therapy.
Of greatest importance is reevaluation, reevaluation, and reevaluation. The patient in shock becomes a new patient every five minutes. Drugs that formerly worked, doses previously optimalthese are no guide because the situation changes so rapidly. The Normally the temperature is about 30°C, but in low cardiac output states it may be as low as 22°C. If cardiac output is increased, by dopamine or other means, the toe temperature increases, and in hyperdynamic states it may reach 35°C. The value of this monitoring system is its ease, precision, and cost: a thermistor is taped to the medial surface of the distal phalanx of the hallux; the measuring system is accurate to + 0.1°C; and the monitor costs less than $25. We have not observed skin necrosis in any of our 370 patients in shock who have received dopamine. I think that skin necrosis may be expected when any potent vasoconstrictor is given to hypoperfused patients with severe vascular disease, and I expect it may occur in some patients given very large doses of dopamine.
Mr P E Ghadiali (London): May I ask Dr Thompson whether he has used steroids in the management of his patients, and also, if he has, whether steroids made any difference to the response to the catecholamines which he has used?
Dr Thompson: Glucocorticoids have been popular in shock because they increase lactate metabolism, stabilize lysosomal membranes, diminish hamoglobin affinity for oxygen, and have other specific beneficial effects in animal models of shock. In patients, however, we were unable to establish a difference in survival in our prospective double-blind study of 60 patients in shock, which I referred to earlier (Thompson et al., 1976, Clinical Research 24, 258A One of the concerns in the use of dopamine is the matter of inducing cardiac arrhythmias. Have you found that, at high doses, you had any higher incidence of cardiac arrhythmias than you had at lower doses? Dr Thompson: The incidence of tachyarrhythmias was not dose-related for the population of patients as a whole, but in any given patient, tachyarrhythmias which had been produced by dopamine abated when the dose was decreased. Many patients who were hypoperfused had ventricular tachyarrhythmias that were ameliorated by dopamine therapy. In our studies tachyarrhythmias were much more frequent with noradrenaline and isoprenaline than with dopamine, but these data are biased by the inclusion of patients who had not responded to these alternative drugs, often because the high doses required had already led to tachyarrhythmias. Nonetheless, on doses producing comparable htmodynamic effects in both sensitive and refractory patients we saw significantly fewer arrhythmias with dopamine. In our experience, when patients were quite refractory and were expiliing, large doses of noradrenaline or isoprenaline often caused tachyarrhythmias during resuscitation, but even in extremis tachyarrhythmias were uncommon with dopamine; the patient usually died with progressive bradycardia.
Another important point is the effect of dopamine on myocardial oxygen consumption and supply. Mueller has shown that isoprenaline is particularly dangerous in shock with myocardial infarction because of its hrmodynamic effects (increased heart rate, decreased aortic diastolic pressure) leading to relative myocardial ischmmia, in contrast with the improved myocardial oxygenation and metabolism achieved with noradrenaline (Mueller H, Ayres S M, Giannelli S jr et al., 1972, Circulation 45, 335) . The hemodynamic effects of dopamine are even more beneficial than those of norepinephrine, because along with a constant heart rate and sustained aortic diastolic pressure there is also effective iedistribution of peripheral perfusion to essential viscera.
One vexing problem is when to give vasodilators and when to give inotropic drugs after myocardial infarction. In regard to this, it is of particular interest that Mueller et al. showed that in shock after myocardial infarction there was loss of coronary vascular autoregulation, so that coronary perfusion became dependent on aortic pressure, especially at mean aortic pressures of less than 65 mmHg. My own practice, therefore, is to permit normotensive patients after myocardial infarction to have mean arterial pressures as low as 65 mmHg without using inotropic drugs, but at lower pressures I institute dopamine.
Professor Dollery (Chairman): There are two points I would like to raise. With these very high doses, if one tries to correlate what you have been saying with what Dr Goldberg was saying earlier, one might expect that you would get severe vasoconstriction in the renal circulation. However, it seems that this does not happen, because you observed an increase in urine flow rate and urine sodium and little change in glomerular filtration rate. It is quite surprising to me that you have been able to give these high doses.
The other question is this: if at these doses you are not having any specific favourable effect on the renal circulationthat is, you are not increasing glomerular filtration or renal blood flow -how would dopamine used in this way look different from a mixture of isoprenaline and noradrenaline? In other words, is there any specific advantage one can point to, or is it merely that its balance of properties is more favourable?
Dr Thompson: These are two very important questions and I will deal with them separately. First, the renal vascular effect of dopamine depends entirely upon the dose range. In healthy anwsthetized dogs in whom we have measured renal blood flow (by an electromagnetic flowmeter) and glomerular filtration (by inulin or exogenous creatinine clearance), the maximum reduction in renal vascular resistance hats occurred with doses of 2 to 8 pg/kg per min (Hochberg M, Gurley H & Thompson W L, 1973, Federation Proceedings 32, 737) . In patients who are only mildly ill with shock or heart failure the maximum increase in glomerular filtration rate occurs in the same dose range (Thompson W L, Gurley H T, Krug U et al., 1975, Clinical Research 23, 224A) . In the more severely ill patients we discussed earlier there were increments in glomerular filtration rate even with doses up to 20 ,ug/kg per min. In most patients given larger doses, who were in severe shock and refractory to therapy, urine flows were quite low and control glomerular filtration rates could not be deter-mined. I believe that such patients have progressive alpha-adrenergic vasoconstriction of the renal (and in our studies mesenteric) vessels. If the patient does not require this 'pressor' effect, administration of an alpha-adrenergic antagonist (phentolamine or phonoxybenzamine) unmasks the primary dopaminergic effect. We have observed that some 50 % of such refractory patients who are anuric during the administration of noradrenaline will more than triple their urinary output when they are switched to dopamine, at doses producing mean arterial pressures comparable to those achieved on noradrenaline.
With regard to your second question I cannot say with certainty that patients in refractory shock will get better distribution of blood flow to essential viscera on high doses of dopamine (say 50-500 ,ug/kg per min) than with himodynamically-equivalent doses of noradrenaline (say 10-100 ,ug/min), but I see no particular reason to add noradrenaline to dopamine or to switch to noradrenaline. With dopamine you have a drug for all patients in shock. The readily-responsive patient given 1-10 ,ug/kg per min gets a profound dopaminergic effect with redistribution of perfusion and an optimal pattern. The less-responsive patient given 11-30 ,ug/kg per min gets a profound beta inotropic effect, with an increase in heart force far greater than can be achieved with digitalis and equal to the effects of isoprenaline or noradrenalineand possibly with fewer tachyarrhythmias. In the refractory patient who has severe hypotension and who requires a pressor effect, dopamine in higher doses causes all of the vasoconstriction that can be achieved with noradrenaline. As the patient improves, however, and lower doses are possible, the dopaminergic effects again become predominant.
